Indication: COVID
A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants from Birth to < 18 Years of Age with COVID-19
Sub-indication: COVID-19 Infection
Study Type: Drug Study
Principal Investigator: Kristina Bryant, M.D.Norton Children's Infectious Diseases, affiliated with the UofL School of Medicine
Sponsor: Sponsor: Gilead Sciences, Inc
